Mental health and visual acuity in patients with age-related macular degeneration.
Age-related macular degeneration
Mental health
Retina
Vison function questionnaires
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
02 Oct 2022
02 Oct 2022
Historique:
received:
31
05
2022
accepted:
07
09
2022
entrez:
1
10
2022
pubmed:
2
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
Visual acuity (VA) loss has been associated with depression in patients with age-related macular degeneration (AMD). However, previous studies did not incorporate subgroups of AMD when correlating VA and mental health. The goal of this study was to describe the relationship between VA and mental health questions in patients with different classifications of AMD, and to identify associations of mental health subscale scores. AMD patients classified by multi-modal imaging were recruited into an AMD registry. Habitual VA was obtained by ophthalmic technicians using the Snellen VA at distance. At enrollment, patients completed the NEI-VFQ-25, which includes 25 questions regarding the patient's visual functionality. Median with interquartile-range (IQR) scores on the mental health subscale of the VFQ were calculated by AMD classification and VA groups. Univariate and multivariable general linear models were used to estimate associations between mental health scores and variables of interest. Eight hundred seventy-five patients were included in the study. Patients with bilateral geographic atrophy (GA) or bilateral GA and neovascular (NV) AMD scored lowest on the mental health subscales with a median (IQR) of 58.2 (38-88) and 59.3 (38-88). When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31-62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81-94). Habitual VA of the better- and worse-seeing eye and AMD classification were significantly associated with mental health subscale scores (all p < 0.0001 in both the univariate and multivariable analysis, except the VA of the worse-seeing eye in multivariable model p = 0.027). Patients enrolled during the COVID pandemic had mental health scores that were 2.7 points lower than prior to the pandemic, but this difference was not significant in univariate (p = 0.300) or multivariable analysis (p = 0.202). There is a significant association between mental health questionnaire scores and AMD classification, as well as VA in both the better and worse-seeing eyes in patients with AMD. It is important for clinicians to recognize feelings of worry/ frustration in these patients, so they can be appropriately referred, screened, and treated for mental health problems.
Sections du résumé
BACKGROUND
BACKGROUND
Visual acuity (VA) loss has been associated with depression in patients with age-related macular degeneration (AMD). However, previous studies did not incorporate subgroups of AMD when correlating VA and mental health. The goal of this study was to describe the relationship between VA and mental health questions in patients with different classifications of AMD, and to identify associations of mental health subscale scores.
METHODS
METHODS
AMD patients classified by multi-modal imaging were recruited into an AMD registry. Habitual VA was obtained by ophthalmic technicians using the Snellen VA at distance. At enrollment, patients completed the NEI-VFQ-25, which includes 25 questions regarding the patient's visual functionality. Median with interquartile-range (IQR) scores on the mental health subscale of the VFQ were calculated by AMD classification and VA groups. Univariate and multivariable general linear models were used to estimate associations between mental health scores and variables of interest.
RESULTS
RESULTS
Eight hundred seventy-five patients were included in the study. Patients with bilateral geographic atrophy (GA) or bilateral GA and neovascular (NV) AMD scored lowest on the mental health subscales with a median (IQR) of 58.2 (38-88) and 59.3 (38-88). When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31-62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81-94). Habitual VA of the better- and worse-seeing eye and AMD classification were significantly associated with mental health subscale scores (all p < 0.0001 in both the univariate and multivariable analysis, except the VA of the worse-seeing eye in multivariable model p = 0.027). Patients enrolled during the COVID pandemic had mental health scores that were 2.7 points lower than prior to the pandemic, but this difference was not significant in univariate (p = 0.300) or multivariable analysis (p = 0.202).
CONCLUSION
CONCLUSIONS
There is a significant association between mental health questionnaire scores and AMD classification, as well as VA in both the better and worse-seeing eyes in patients with AMD. It is important for clinicians to recognize feelings of worry/ frustration in these patients, so they can be appropriately referred, screened, and treated for mental health problems.
Identifiants
pubmed: 36183081
doi: 10.1186/s12886-022-02602-9
pii: 10.1186/s12886-022-02602-9
pmc: PMC9526530
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
391Subventions
Organisme : NEI NIH HHS
ID : R01 EY032456
Pays : United States
Investigateurs
Melanie Akau
(M)
Karen L Christopher
(KL)
Richard Davidson
(R)
Ruth T Eshete
(RT)
C Rob Graef
(CR)
Scott Hauswirth
(S)
Anne M Lynch
(AM)
Scott N Oliver
(SN)
Jeffery L Olson
(JL)
Alan G Palestine
(AG)
Jesse M Smith
(JM)
Brandie D Wagner
(BD)
Informations de copyright
© 2022. The Author(s).
Références
J Int Med Res. 2011;39(4):1142-54
pubmed: 21986116
J Affect Disord. 2021 Feb 15;281:91-98
pubmed: 33310451
Restor Neurol Neurosci. 2018;36(6):767-791
pubmed: 30412515
Retina. 2019 Apr;39(4):656-663
pubmed: 29283981
Can J Ophthalmol. 2013 Oct;48(5):381-5
pubmed: 24093184
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):205-15
pubmed: 17896299
Ophthalmol Retina. 2019 Apr;3(4):336-342
pubmed: 31014686
Med Hypothesis Discov Innov Ophthalmol. 2019 Winter;8(4):306-311
pubmed: 31788493
Am J Ophthalmol. 2021 Jun;226:148-155
pubmed: 33529583
Clin Ophthalmol. 2015 Dec 30;10:55-63
pubmed: 26766899
Arch Ophthalmol. 2012 Sep;130(9):1162-8
pubmed: 22965592
BMC Ophthalmol. 2014 Jun 12;14:78
pubmed: 24923726
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Indian J Ophthalmol. 2008 Nov-Dec;56(6):469-74
pubmed: 18974517
J Nutr Health Aging. 2020;24(9):938-947
pubmed: 33155618
Arch Ophthalmol. 2001 Jul;119(7):1050-8
pubmed: 11448327
J Gerontol A Biol Sci Med Sci. 2002 Mar;57(3):M150-1
pubmed: 11867649
Sci Rep. 2020 Mar 16;10(1):4816
pubmed: 32179798
Clin Interv Aging. 2017 Oct 03;12:1579-1587
pubmed: 29042759
BMJ Open. 2016 Dec 2;6(12):e011504
pubmed: 27913556
BMJ Open Ophthalmol. 2020 Jan 14;5(1):e000361
pubmed: 32509962
Ophthalmic Physiol Opt. 2021 Mar;41(2):255-265
pubmed: 33427324
Acta Ophthalmol. 2021 Nov;99(7):750-755
pubmed: 33377625
Arch Ophthalmol. 2002 Aug;120(8):1041-4
pubmed: 12149057
Ophthalmology. 2006 Oct;113(10):1743-7
pubmed: 16893569
Curr Opin Ophthalmol. 2013 May;24(3):239-43
pubmed: 23429599
Lancet. 2005 Jun 4-10;365(9475):1961-70
pubmed: 15936426
Ophthalmology. 2004 Dec;111(12):2259-64
pubmed: 15582083